ECSP21059253A - Proceso para la preparación de comprimidos fáciles de tomar que contienen extracto seco de hojas de ginkgo biloba - Google Patents

Proceso para la preparación de comprimidos fáciles de tomar que contienen extracto seco de hojas de ginkgo biloba

Info

Publication number
ECSP21059253A
ECSP21059253A ECSENADI202159253A ECDI202159253A ECSP21059253A EC SP21059253 A ECSP21059253 A EC SP21059253A EC SENADI202159253 A ECSENADI202159253 A EC SENADI202159253A EC DI202159253 A ECDI202159253 A EC DI202159253A EC SP21059253 A ECSP21059253 A EC SP21059253A
Authority
EC
Ecuador
Prior art keywords
dry extract
ginkgo biloba
preparation
biloba leaves
tablets containing
Prior art date
Application number
ECSENADI202159253A
Other languages
English (en)
Inventor
Joachim Herrmann
Andreas Rothe
Original Assignee
Dr Willmar Schwabe Gmbh Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65033398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP21059253(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dr Willmar Schwabe Gmbh Co filed Critical Dr Willmar Schwabe Gmbh Co
Publication of ECSP21059253A publication Critical patent/ECSP21059253A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un proceso para la preparación de un comprimido de desintegración rápida con un tiempo de desintegración de 15 minutos como máximo para la administración peroral de un extracto seco de las hojas de Ginkgo biloba y con un peso total del comprimido entre 150 mg y 300 mg por cada 100 mg de extracto de ginkgo contenido. También es un objetivo de la invención proporcionar comprimidos de desintegración rápida que contengan extracto seco de las hojas de Ginkgo biloba, las cuales, debido a sus dimensiones más pequeñas, son más fáciles de tomar que los comprimidos utilizados hasta ahora. En una modalidad preferida, los comprimidos no contienen lactosa por lo tanto también son bien tolerados.
ECSENADI202159253A 2019-01-15 2021-08-11 Proceso para la preparación de comprimidos fáciles de tomar que contienen extracto seco de hojas de ginkgo biloba ECSP21059253A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19151878.6A EP3682870B1 (de) 2019-01-15 2019-01-15 Verfahren zur herstellung von leicht einzunehmenden tabletten mit trockenextrakt aus ginkgo biloba blättern

Publications (1)

Publication Number Publication Date
ECSP21059253A true ECSP21059253A (es) 2021-09-30

Family

ID=65033398

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202159253A ECSP21059253A (es) 2019-01-15 2021-08-11 Proceso para la preparación de comprimidos fáciles de tomar que contienen extracto seco de hojas de ginkgo biloba

Country Status (23)

Country Link
US (1) US20220080006A1 (es)
EP (2) EP3682870B1 (es)
JP (1) JP7382409B2 (es)
KR (1) KR102772003B1 (es)
CN (1) CN113365612B (es)
AU (1) AU2020208564A1 (es)
CL (1) CL2021001668A1 (es)
CO (1) CO2021010578A2 (es)
EC (1) ECSP21059253A (es)
ES (1) ES2958082T3 (es)
HR (1) HRP20231170T1 (es)
HU (1) HUE063900T2 (es)
IL (1) IL284825B2 (es)
MA (1) MA53570B1 (es)
MX (1) MX2021008522A (es)
MY (1) MY204292A (es)
PH (1) PH12021551506A1 (es)
PL (1) PL3682870T3 (es)
PT (1) PT3682870T (es)
RS (1) RS64615B1 (es)
SG (1) SG11202107094XA (es)
TN (1) TN2021000116A1 (es)
WO (1) WO2020148125A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023050584A (ja) * 2021-09-30 2023-04-11 旭化成株式会社 錠剤用組成物及び錠剤
WO2023246722A1 (en) * 2022-06-20 2023-12-28 Aptorum Therapeutics Limited Dioscorea polystachya tablet formulation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3338995A1 (de) 1983-10-27 1985-05-09 Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe Bilobalid enthaltende arzneimittel
US5895785A (en) 1987-10-20 1999-04-20 Ruth Korth Treatment and prevention of disorders mediated by LA-paf or endothelial cells
DE3735525C2 (de) 1987-10-20 1997-02-20 Korth Ruth Maria Verfahren zur Bestimmung der Wirksamkeit von paf-Acether-Rezeptor-Antagonisten
DE3940091A1 (de) 1989-12-04 1991-06-06 Schwabe Willmar Gmbh & Co Extrakt aus blaettern von ginkgo biloba, verfahren zu seiner herstellung und den extrakt enthaltende arzneimittel
DE540767T1 (de) 1991-11-04 2001-10-25 Ruth-Maria Korth Behandlung und Vorbeugung von von erhöhten Lyso-PAF-Spiegel mediierten mentalen Erkrankungen mit PAF-Antagonisten
DE19509856C2 (de) 1995-03-17 1997-09-11 Schwabe Willmar Gmbh & Co Verwendung einer Brausezusammensetzung mit Ginkgo-Biloba Trockenextrakt zur Behandlung peripherer und cerebraler Durchblutungsstörungen
CN1623593A (zh) * 2003-12-05 2005-06-08 北京博尔达生物技术开发有限公司 银杏叶提取物固体速溶制剂及制备方法
CN1237981C (zh) * 2003-12-31 2006-01-25 北京科信必成医药科技发展有限公司 银杏叶口腔崩解片及其制备方法
CN1273116C (zh) * 2004-06-22 2006-09-06 张晴龙 一种银杏叶口腔崩解片及其制备方法
DE102005014272A1 (de) * 2005-03-24 2006-09-28 Rhein Chemie Rheinau Gmbh Mikrogele und Verdickungsmittel enthaltende Zusammensetzungen
CN1939355A (zh) * 2005-09-30 2007-04-04 江西本草天工科技有限责任公司 银杏叶分散片
DE102005062417A1 (de) 2005-12-27 2007-08-23 Korth, Ruth-Maria, Dr.med. Kompositionen mit spezifischen und unspezifischen Lipidantagonisten
CN101460150B (zh) * 2006-03-31 2014-02-12 鲁比康研究私人有限公司 用于口腔崩解片剂的可直接压片复合物
JP4976500B2 (ja) * 2007-09-19 2012-07-18 アサヒグループホールディングス株式会社 漢方エキス、生薬エキスあるいは天然物抽出エキスまたはそれらの混合物等の天然物由来物質を含有する顆粒物の製造方法およびその顆粒物から製造する錠剤の製造方法
ES2709633T3 (es) * 2007-12-21 2019-04-17 Dr Willmar Schwabe Gmbh & Co Kg Uso de un extracto de hojas de Ginkgo biloba
MX341428B (es) 2011-04-27 2016-08-18 Dr Willmar Schwabe Gmbh & Co Kg Tableta de liberacion controlada de extracto de ginkgo biloba y procedimiento para su obtencion.
DE202011108417U1 (de) 2011-11-29 2012-03-01 Ruth-Maria Korth Örtliche und dietätische Kompositionen ohne Etherlipide, Etherphospholipide, Alkylradikale, die geeignet sind für sensible Personen
CN103976967A (zh) * 2014-06-04 2014-08-13 湖南科技学院 一种银杏内酯舌下片及其制备方法
DE202014005450U1 (de) 2014-07-04 2015-10-06 Ursapharm Arzneimittel Gmbh Lactosefreies Arzneimittel

Also Published As

Publication number Publication date
EP3682870B1 (de) 2023-08-30
JP7382409B2 (ja) 2023-11-16
CA3122196A1 (en) 2020-07-23
AU2020208564A1 (en) 2021-06-24
MA53570A1 (fr) 2022-06-30
MA53570B1 (fr) 2023-01-31
TN2021000116A1 (en) 2023-01-05
KR20210114974A (ko) 2021-09-24
IL284825A (en) 2021-08-31
PL3682870T3 (pl) 2023-12-11
HUE063900T2 (hu) 2024-02-28
ES2958082T3 (es) 2024-02-01
IL284825B1 (en) 2024-10-01
MY204292A (en) 2024-08-21
SG11202107094XA (en) 2021-07-29
IL284825B2 (en) 2025-02-01
EP4248955A2 (de) 2023-09-27
CN113365612A (zh) 2021-09-07
MX2021008522A (es) 2021-11-12
HRP20231170T1 (hr) 2024-01-19
CL2021001668A1 (es) 2021-12-31
JP2022518163A (ja) 2022-03-14
CO2021010578A2 (es) 2021-08-30
PT3682870T (pt) 2023-09-25
CN113365612B (zh) 2023-11-17
PH12021551506A1 (en) 2022-03-07
EP4248955A3 (de) 2023-11-22
KR102772003B1 (ko) 2025-02-26
RS64615B1 (sr) 2023-10-31
US20220080006A1 (en) 2022-03-17
WO2020148125A1 (de) 2020-07-23
EP3682870A1 (de) 2020-07-22

Similar Documents

Publication Publication Date Title
CL2020002841A1 (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
CO2020015153A2 (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
CL2021001609A1 (es) Régimen de dosificación y combinación farmacéutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
MX2021004191A (es) Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
CO2022002374A2 (es) Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
MX2017015838A (es) Composiciones y metodos para tratar pterigion.
MX2019007587A (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
MX2016010053A (es) Composiciones de compuestos y usos de los mismos.
ECSP21059253A (es) Proceso para la preparación de comprimidos fáciles de tomar que contienen extracto seco de hojas de ginkgo biloba
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
MX2018016330A (es) Combinaciones para tratamiento del cáncer.
SV2017005595A (es) Unidad de dosificacion orodispersable que contiene un componente estetrol
CL2017001301A1 (es) Composiciones oftálmicas estabilizadas de omega 3
PE20211588A1 (es) Compuestos y sus usos para aliviar sintomas asociados a la menopausia
MX2018015022A (es) Métodos para el tratamiento de la enfermedad de alzheimer.
CO2019015102A2 (es) Nuevos derivados de xantina sustituidos
MX2017003469A (es) Inhibidores macrociclicos de cinasa rip2.
CL2019000532A1 (es) Polimorfos cristalinos de un agonista del receptor de acetilcolina muscarínico.
MX2018013969A (es) Combinacion de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda.
MX391400B (es) Formulaciones farmacéuticas de matriz que comprenden dimetilfumarato.
EA201992142A1 (ru) Фармацевтические композиции и их применения
ES2582494A1 (es) Prótesis dental
BR112018072583A2 (pt) composição farmacêutica de comprimido em comprimido estável
MX2022007020A (es) Productos orales con combinaciones de ingredientes activos.
CL2019001462A1 (es) Composición mejorada de lansoprazol y simeticona y proceso para prepararla.